Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

New Headgear Device Delivers Pain Relief For Fibromyalgia And Migraine

Wednesday 27 January 2016


From MD Magazine:



New Headgear Device Delivers Pain Relief for Fibromyalgia and Migraine

Caitlyn Fitzpatrick
25 January 2016

Fibromyalgia and migraine headaches are just two pain conditions that debilitate millions of people. A new pain-relieving device has just been approved for both of the conditions, but there’s a catch.

The PainX tDCS Therapy device received the CE Mark approval after 14 studies over the course of eight years resulted in positive results for multiple painful conditions, including spinal cord injury. However, the device is only available on the European market for now.

“Many chronic pain disorders are associated with neuropathic pain, meaning pain that originates through maladaptive plasticity in the brain,” Abhishek Datta, PhD, CTO of Soterix Medical, explained in a news release.

The battery-powered device delivers a low-intensity current to the cerebral cortex. The PainX headgear works by either controlling perception of pain or altering the reacting to pain. It does this by enhancing “adaptive plasticity encouraging correction of brain activity.” The developers reassure patients that the therapy underwent five years of design and testing for not just efficacy, but safety as well.

“The CE approval allows our unique tDCS technology to provide an effective, safe and well-tolerated solution for the severe conditions like fibromyalgia, migraine, and other forms of chronic pain,” said Shani San Solo, VP Europe Business for Soterix Medical.

Some of the studies showed the patients continued to reap the benefits of the PainX for three to 12 weeks following treatment. Itching and tingling were the most side effects and in rare cases headache occurred.

All in favor of moving forward for the American market?

Copyright MD Magazine.
2006-2015 Intellisphere, LLC.
All Rights Reserved.


The above originally appeared here.


Arrow right

More Fibromyalgia News



blog comments powered by Disqus

Previous Previous Page